Menu Back toBrave New World: Early Clinical Trials in a Pandemic
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Brave New World: Early Clinical Trials in a Pandemic
- Executive Vice President, Translational Medicine
- Parexel, United States
This session will discuss the impact on early clinical research and development under COVID-19 and measures that were put in place to protect healthy volunteers and staff.
Learning Objective : To understand the impact on early clinical research and early drug development under COVID-19 pandemic conditions. To identify & refine safety measures and operational setup for volunteers/staff under COVID-19 pandemic conditions. To analyze the impact on the COVID-19 pandemic on early clinical research in general and in particular in Germany.
SARS-CoV-2 Testing, Operational Challenges, and Subject Safety Considerations Under COVID-19 Pandemic Conditions: A New Era
Sandra Stark, PhD, MSc
- Head Early Phase Clinical Unit Berlin
- Parexel International, Germany
Early Clinical Trials in a Pandemic: A Big Pharma Story
Jessie Gu, PhD
- Executive Director, Global Head, Ph1 Clinical Pharmacology
- Novartis Institutes for BioMedical Research (NIBR), United States